Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1459-1470

  Bonami, Rachel H ^a   Sullivan, Allison M ^a   Case, James B ^a   Steinberg, Hannah E ^a   Hoek, Kristen L ^a   Khan, Wasif N ^b   Kendall, Peggy L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; IMMUNOGLOBULINS; INSULIN; INSULIN ANTIBODIES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL;

EID: 84896732681     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300125     Document Type: Article

References (47)

1. Merrell, K. T., R. J. Benschop, S. B. Gauld, K. Aviszus, D. Decote-Ricardo, L. J. Wysocki, and J. C. Cambier. 2006. Identification of anergic B cells within a wild-type repertoire. Immunity 25: 953-962.
2. Duty, J. A., P. Szodoray, N. Y. Zheng, K. A. Koelsch, Q. Zhang, M. Swiatkowski, M. Mathias, L. Garman, C. Helms, B. Nakken, et al. 2009. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J. Exp. Med. 206: 139-151.
3. Quach, T. D., N. Manjarrez-Orduno, D. G. Adlowitz, L. Silver, H. Yang, C. Wei, E. C. Milner, and I. Sanz. 2011. Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. J. Immunol. 186: 4640-4648.
4. Zikherman, J., R. Parameswaran, and A. Weiss. 2012. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489: 160-164.
5. Rojas, M., C. Hulbert, and J. W. Thomas. 2001. Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen. J. Immunol. 166: 3194-3200.
6. Acevedo-Suárez, C. A., C. Hulbert, E. J. Woodward, and J. W. Thomas. 2005. Uncoupling of anergy from developmental arrest in anti-insulin B cells supports the development of autoimmune diabetes. J. Immunol. 174: 827-833.
7. Hulbert, C., B. Riseili, M. Rojas, and J. W. Thomas. 2001. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 167: 5535-5538.
8. Kendall, P. L., J. B. Case, A. M. Sullivan, J. S. Holderness, K. S. Wells, E. Liu, and J. W. Thomas. 2013. Tolerant anti-insulin B cells are effective APCs. J. Immunol. 190: 2519-2526.
9. Schroer, J. A., T. Bender, R. J. Feldmann, and K. J. Kim. 1983. Mapping epitopes on the insulin molecule using monoclonal antibodies. Eur. J. Immunol. 13: 693-700.
10. Benschop, R. J., E. Brandl, A. C. Chan, and J. C. Cambier. 2001. Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation. J. Immunol. 167: 4172-4179.
11. Kitamura, D., J. Roes, R. Kühn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350: 423-426.
12. Dal Porto, J. M., S. B. Gauld, K. T. Merrell, D. Mills, A. E. Pugh-Bernard, and J. Cambier. 2004. B cell antigen receptor signaling 101. Mol. Immunol. 41: 599-613.
13. Petro, J. B., I. Castro, J. Lowe, and W. N. Khan. 2002. Bruton's tyrosine kinase targets NF-kappaB to the bcl-x promoter via a mechanism involving phospholipase C-gamma2 following B cell antigen receptor engagement. FEBS Lett. 532: 57-60.
14. Khan, W. N., F. W. Alt, R. M. Gerstein, B. A. Malynn, I. Larsson, G. Rathbun, L. Davidson, S. Müller, A. B. Kantor, L. A. Herzenberg, et al. 1995. Defective B cell development and function in Btk-deficient mice. Immunity 3: 283-299.
15. Shinners, N. P., G. Carlesso, I. Castro, K. L. Hoek, R. A. Corn, R. T. Woodland, M. L. Scott, D. Wang, and W. N. Khan. 2007. Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family. [Published erratum appears in 2007 J. Immunol. 179: 6369.] J. Immunol. 179: 3872-3880.
16. Antony, P., J. B. Petro, G. Carlesso, N. P. Shinners, J. Lowe, and W. N. Khan. 2004. B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol. Biochem. Soc. Trans. 32: 113-115.
17. Antony, P., J. B. Petro, G. Carlesso, N. P. Shinners, J. Lowe, and W. N. Khan. 2003. B cell receptor directs the activation of NFAT and NF-kappaB via distinct molecular mechanisms. Exp. Cell Res. 291: 11-24.
18. Khan, W. N. 2001. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol. Res. 23: 147-156.
19. Petro, J. B., and W. N. Khan. 2001. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J. Biol. Chem. 276: 1715-1719.
20. Petro, J. B., S. M. Rahman, D. W. Ballard, and W. N. Khan. 2000. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J. Exp. Med. 191: 1745-1754.
21. Kil, L. P., M. J. de Bruijn, M. van Nimwegen, O. B. Corneth, J. P. van Hamburg, G. M. Dingjan, F. Thaiss, G. F. Rimmelzwaan, D. Elewaut, D. Delsing, et al. 2012. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119: 3744-3756.
22. -/- mice. J. Immunol. 171: 1850-1858.
23. Aalipour, A., and R. H. Advani. 2013. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br. J. Haematol. 163: 436-443.
24. Chang, B. Y., M. Francesco, M. F. De Rooij, P. Magadala, S. M. Steggerda, M. M. Huang, A. Kuil, S. E. Herman, S. Chang, S. T. Pals, et al. 2013. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122: 2412-2424.
25. de Rooij, M. F., A. Kuil, C. R. Geest, E. Eldering, B. Y. Chang, J. J. Buggy, S. T. Pals, and M. Spaargaren. 2012. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119: 2590-2594.
26. Rossi, D., C. Ciardullo, V. Spina, and G. Gaidano. 2013. Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunol. Lett. 155: 51-55.
27. Kendall, P. L., D. J. Moore, C. Hulbert, K. L. Hoek, W. N. Khan, and J. W. Thomas. 2009. Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J. Immunol. 183: 6403-6412.
28. Serreze, D. V., S. A. Fleming, H. D. Chapman, S. D. Richard, E. H. Leiter, and R. M. Tisch. 1998. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 161: 3912-3918.
29. Serreze, D. V., H. D. Chapman, D. S. Varnum, M. S. Hanson, P. C. Reifsnyder, S. D. Richard, S. A. Fleming, E. H. Leiter, and L. D. Shultz. 1996. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 184: 2049-2053.
30. Noorchashm, H., Y. K. Lieu, N. Noorchashm, S. Y. Rostami, S. A. Greeley, A. Schlachterman, H. K. Song, L. E. Noto, A. M. Jevnikar, C. F. Barker, and A. Naji. 1999. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J. Immunol. 163: 743-750.
31. Pelanda, R., S. Schwers, E. Sonoda, R. M. Torres, D. Nemazee, and K. Rajewsky. 1997. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 7: 765-775.
32. Henry, R. A., C. A. Acevedo-Suárez, and J. W. Thomas. 2009. Functional silencing is initiated and maintained in immature anti-insulin B cells. J. Immunol. 182: 3432-3439.
33. Pereira, J. P., J. An, Y. Xu, Y. Huang, and J. G. Cyster. 2009. Cannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoids. Nat. Immunol. 10: 403-411.
34. Allman, D., R. C. Lindsley, W. DeMuth, K. Rudd, S. A. Shinton, and R. R. Hardy. 2001. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J. Immunol. 167: 6834-6840.
35. Fluckiger, A. C., Z. Li, R. M. Kato, M. I. Wahl, H. D. Ochs, R. Longnecker, J. P. Kinet, O. N. Witte, A. M. Scharenberg, and D. J. Rawlings. 1998. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J. 17: 1973-1985.
36. Takata, M., and T. Kurosaki. 1996. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J . Exp. Med. 184: 31-40.
37. Middendorp, S., and R. W. Hendriks. 2004. Cellular maturation defects in Bruton's tyrosine kinase-deficient immature B cells are amplified by premature B cell receptor expression and reduced by receptor editing. J. Immunol. 172: 1371-1379.
38. Middendorp, S., G. M. Dingjan, A. Maas, K. Dahlenborg, and R. W. Hendriks. 2003. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. J. Immunol. 171: 5988-5996.
39. Honigberg, L. A., A. M. Smith, M. Sirisawad, E. Verner, D. Loury, B. Chang, S. Li., Z. Pan, D. H. Thamm, R. A. Miller, and J. J. Buggy. 2010. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA 107: 13075-13080.
40. de Gorter, D. J., E. A. Beuling, R. Kersseboom, S. Middendorp, J. M. van Gils, R. W. Hendriks, S. T. Pals, and M. Spaargaren. 2007. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26: 93-104.
41. Sharma, S., G. Orlowski, and W. Song. 2009. Btk regulates B cell receptormediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J. Immunol. 182: 329-339.
42. Fulcher, D. A., and A. Basten. 1994. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp. Med. 179: 125-134.
43. Yarkoni, Y., A. Getahun, and J. C. Cambier. 2010. Molecular underpinning of Bcell anergy. Immunol. Rev. 237: 249-263.
44. Henry, R. A., P. L. Kendall, and J. W. Thomas. 2012. Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes. Diabetes 61: 2037-2044.
45. Braun, U., K. Rajewsky, and R. Pelanda. 2000. Different sensitivity to receptor editing of B cells from mice hemizygous or homozygous for targeted Ig transgenes. Proc. Natl. Acad. Sci. USA 97: 7429-7434.
46. Nündel, K., P. Busto, M. Debatis, and A. Marshak-Rothstein. 2013. The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells. J. Leukoc. Biol. 94: 865-875.
47. Barral, P. 2013. Editorial: Btk - friend or foe in autoimmune diseases? J. Leukoc. Biol. 94: 859-861.